We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
90Y-edotreotide for metastatic carcinoid refractory to octreotide.
- Authors
Bushnell, David L, Jr; O'Dorisio, Thomas M; O'Dorisio, M Sue; Menda, Yusuf; Hicks, Rodney J; Van Cutsem, Eric; Baulieu, Jean-Louis; Borson-Chazot, Francoise; Anthony, Lowell; Benson, Al B; Oberg, Kjell; Grossman, Ashley B; Connolly, Mary; Bouterfa, Hakim; Li, Yong; Kacena, Katherine A; LaFrance, Norman; Pauwels, Stanislas A
- Abstract
Metastatic carcinoid is an incurable malignancy whose symptoms, such as diarrhea and flushing, can be debilitating and occasionally life-threatening. Although symptom relief is available with octreotide, the disease eventually becomes refractory to octreotide, leaving no proven treatment options. The goal of this study was to evaluate the clinical effect of using (90)Y-edotreotide to treat symptomatic patients with carcinoid tumors.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Vol 28, Issue 10, p1652
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2009.22.8585